Frederick National Laboratory for Cancer Research

4 articles published in JoVE

• Biochemistry

  
  Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein Constance Agamasu¹, Peter Frank¹, Shelley Perkins¹, Timothy Waybright¹, Simon Messing¹, William Gillette¹, Andrew G. Stephen^{1 1}NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research Prenylation is an important modification on peripheral membrane binding proteins. Insect cells can be manipulated to produce farnesylated and carboxymethylated KRAS4b in quantities that enable biophysical measurements of protein-protein and protein-lipid interactions

• Bioengineering

  
  Detection of Endotoxin in Nano-formulations Using Limulus Amoebocyte Lysate (LAL) Assays Barry W. Neun¹, Marina A. Dobrovolskaia^{1 1}Nanotechnology Characterization Lab., Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by National Cancer Institute Detection of endotoxins in engineered nanomaterials represents one of the grand challenges in the field of nanomedicine. Here, we present a case study that describes the framework composed of three different LAL formats to estimate potential endotoxin contamination in nanoparticles.

• Chemistry

  
  Synthesis of Cd-free InP/ZnS Quantum Dots Suitable for Biomedical Applications Matthew A. Ellis¹, Giovanna Grandinetti², Katye M. Fichter^{1 1}Department of Chemistry, Missouri State University, ²Center for Molecular Microscopy, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research In this protocol, the synthesis of Cd-free InP/ZnS quantum dots (QDs) is detailed. InP-based QDs are gaining popularity due to the toxicity of Cd²⁺ ions that may be released through nanoparticle degradation. After synthesis, QDs are solubilized in water using an amphiphilic polymer for use in biomedical applications.

• Neuroscience

  
  A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors Krishna P. Kota^1,6, Veronica Soloveva^2,6,7, Laura M. Wanner^3,6, Glenn Gomba^4,6, Erkan Kiris^3,5,6, Rekha G. Panchal⁶, Christopher D. Kane^2,6,7, Sina Bavari^{6 1}Perkin Elmer Inc., ²Henry M. Jackson Foundation, ³The Geneva Foundation, ⁴ORISE, ⁵Frederick National Laboratory for Cancer Research, ⁶Division of Molecular and Translational Sciences, US Army Medical Research Institute of Infectious Diseases, ⁷DoD Biotechnology High Performance Computing Software Applications Institute (BHSAI), Telemedicine and Advanced Technology Research Center (TATRC), US Army Medical Research and Materiel Command (USAMRMC) Botulinum neurotoxin is one of the most potent toxins among Category-A biothreat agents, yet a post-exposure therapeutic is not available. The high content imaging approach is a powerful methodology for identifying novel inhibitors as it enables multiparameter screening using biologically relevant motor neurons, the primary target of this toxin.